The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives—in particular, disease-modifying therapies (DMTs) that can slow the course of the disease. In response, drug developers—from big pharma to small biotech—continue to invest heavily in disease-modifying approaches owing to the tremendous clinical and commercial opportunity in this arena, despite decades of late-phase failures. Although many uncertainties remain about the launch prospects for late-phase anti-amyloid MAbs from Biogen, Eisai, and Roche, key opinion leaders (KOLs) have expressed cautious optimism about these agents and the numerous anti-tau therapies in early- to mid-phase trials. Meanwhile, hope remains for late-phase therapies from Lundbeck/Otsuka, Otsuka/Avanir, and Axsome that are in development for key AD agitation, a key neuropsychiatric symptom. Ultimately, however, the launch of any of these agents is far from guaranteed.

QUESTIONS ANSWERED

  • What are the drivers and constraints in the AD market?
  • How large is the treatable AD population by key segments?
  • What clinical and commercial impact can be expected from DMTs and neurospsychiatric therapies, should they launch? Which populations will be most affected?
  • What are experts’ opinions of the launch prospects for agents in development?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • November 2020
      • Q3 2020
        • July 2020
    • Key Findings
      • Alzheimer's Disease Key Findings - June 2021
        • July 2020
    • Market Outlook
      • Key Findings
        • Market Share of Alzheimer's Disease Drug Classes: 2019
        • Market Share of Alzheimer's Disease Drug Classes: 2029
        • Alzheimer's Disease SWOT Analysis
      • COVID-19: Areas of Potential Forecast Impact
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Alzheimer's Disease?
          • What Factors Are Constraining the Market for Alzheimer's Disease?
          • Major-Market Sales of Alzheimer's Disease Therapies by Disease Subtype: 2019-2029
          • Major-Market Drug-Treated Alzheimer's Disease Patient Populations: 2019-2029
        • Drug-Class-Specific Trends
          • Major-Market Sales of Behavioral Therapies in Alzheimer's Disease: 2019-2029
          • Major-Market Patient Share of Behavioral Therapies in Alzheimer's Disease: 2019-2029
          • Anti-Aβ Monoclonal Antibodies
          • The Cost of Disease-Modifying Therapy in Alzheimer's Disease
          • Major-Market Sales and Patient Share of Disease-Modifying Therapies in MCI due to AD: 2019-2029
          • Major-Market Sales and Patient Share of Disease-Modifying Therapies in Mild AD: 2019-2029
          • Major-Market Sales in Alzheimer's Disease, by Therapeutic Group: 2019-2029
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease Overview
          • Amyloid Plaques and Neurofibrillary Tangles in Alzheimer’s Disease
        • Etiology
          • Genetic Risk Factors for Alzheimer's Disease
          • Genes Associated with Familial Alzheimer’s Disease
          • Nongenetic Risk Factors for Alzheimer's Disease
        • Pathophysiology
          • Leading Pathophysiological Hypotheses in Alzheimer's Disease
          • Normal and Pathogenic Cleavage of Amyloid Precursor Protein
        • Disease Progression / Natural History
          • Brain Atrophy in Alzheimer’s Disease
        • Key Pathways and Drug Targets
          • Key Drug Targets
          • Key Strategies and Drug Targets in Alzheimer's Disease
      • Epidemiology
        • Key Findings
          • Epidemiology Populations
            • 2020 Model Update
            • Disease Definition
            • Methods
            • Sources Used for Total Prevalent Cases of Asymptomatic Alzheimer’s Disease
            • Total Prevalent Cases of Asymptomatic Alzheimer’s Disease in the Mature Pharmaceutical Markets: 2019-2029 (thousands)
            • Disease Definition
            • Methods
            • Sources Used for Total MCI due to AD
            • Total Prevalent Cases of MCI due to AD in the Mature Pharmaceutical Markets: 2019-2029 (Thousands)
            • Disease Definition
            • Methods
            • Sources Used for Total Prevalent Cases of Alzheimer’s Disease
            • Total Prevalent Cases of Alzheimer's Disease in the Mature Pharmaceutical Markets: 2019-2029 (Thousands)
            • Multistate Model of the Progression of Alzheimer's Disease
            • Disease Definition
            • Methods
            • Sources Used for Total Prevalent Cases of Alzheimer's Disease by Severity
            • Total Prevalent Cases of Alzheimer's Disease by Severity in the Mature Pharmaceutical Markets: 2019-2029 (thousands)
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Prevalent Cases of Alzheimer's Disease by Symptom Status
            • Diagnosed Prevalent Cases of Alzheimer's Disease by Symptom Status in the Mature Pharmaceutical Markets: 2019-2029 (Thousands)
            • Diagnosed Prevalent Cases of MCI due to AD in the Mature Pharmaceutical Markets: 2019-2029 (Thousands)
            • Diagnosed Prevalent Cases of Alzheimer's Disease by Severity in the Mature Pharmaceutical Markets: 2019-2029 (Thousands)
            • Drug-Treated Prevalent Cases of MCI due to AD in the Mature Pharmaceutical Markets: 2019-2029 (Thousands)
            • Drug-Treated Prevalent Cases of Alzheimer's Disease by Severity in the Mature Pharmaceutical Markets: 2019-2029 (Thousands)
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Alzheimer's Disease
            • Key Current Therapies
              • Overview of Alzheimer's Disease Drug Classification
              • Mechanism of Action of Key Current Drug Classes Used for Alzheimer’s Disease
              • Current Treatments Used for Alzheimer’s Disease
              • Market Events Impacting the Use of Key Current Therapies in Alzheimer's Disease
              • Advantages and Disadvantages of Donepezil
              • Advantages and Disadvantages of Rivastigmine
              • Advantages and Disadvantages of Galantamine
              • Advantages and Disadvantages of Memantine
              • Advantages and Disadvantages of Antipsychotics
              • Advantages and Disadvantages of Antidepressants
              • Revised Diagnostic Guidelines
              • Summary of Diagnostic Guidelines for Alzheimer’s Disease and Subsequent Revisions
              • Diagnostic Biomarkers
              • Non-PET-Imaging-Related Diagnostic Biomarkers
              • PET Imaging
              • Factors Influencing the Use of PET Imaging Biomarkers
            • Medical Practice
              • Overview
              • Alzheimer’s Disease Treatment Guidelines by Market
              • Factors Influencing Drug Selection in Alzheimer’s Disease
              • Region-Specific Treatment Practices
              • Treatment Decision Tree for Alzheimer's Disease: United States
              • Treatment Decision Tree for Alzheimer's Disease: Europe
              • Treatment Decision Tree for Alzheimer's Disease: Japan
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in Alzheimer's Disease
            • Top Unmet Needs in Alzheimer's Disease: Current and Future Attainment
            • Expert Insight: Unmet Need in Alzheimer's Disease
          • Emerging Therapies
            • Key Findings
              • Key Emerging Therapies
                • Key Therapies in Development for Alzheimer's Disease
                • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Alzheimer's Disease
                • Drug Development and Regulatory Hurdles
                • Drug Development and Regulatory Hurdles in Alzheimer's Disease
                • Select Ongoing Clinical Trials of Disease-Modifying Therapies in the Treatment of Alzheimer's Disease
                • Select Ongoing Prevention Trials in Alzheimer’s Disease
                • Key Results from Select Clinical Trials Investigating Aducanumab for the Treatment of Alzheimer's Disease
                • Analysis of the Clinical Development Program for Aducanumab
                • Expert Insight: Aducanumab
                • Expectations for Launch and Sales Opportunity of Aducanumab in Alzheimer's Disease
                • Key Results from Select Clinical Trials Investigating Lecanemab for the Treatment of Alzheimer's Disease
                • Analysis of the Clinical Development Program for Lecanemab
                • Expert Insight: Lecanemab
                • Expectations for Launch and Sales Opportunity of Lecanemab in Alzheimer's Disease
                • Key Results from Select Clinical Trials Investigating Gantenerumab for the Treatment of Alzheimer's Disease
                • Analysis of the Clinical Development Program for Gantenerumab
                • Expert Insight: Gantenerumab
                • Expectations for Launch and Sales Opportunity of Gantenerumab in Alzheimer's Disease
                • Likely Uses of Behavioral Therapies for the Treatment of Agitation Associated with Alzheimer's Disease
                • Rexulti Profile
                • Analysis of the Clinical Development Program of Rexulti
                • Expert Insight: Rexulti
                • Expectations for Launch and Sales Opportunity of Rexulti in Alzheimer's Disease
                • Nuplazid Profile
                • Analysis of the Clinical Development Program for Nuplazid
                • Expert Insight: Nuplazid
                • Expectations for Launch and Sales Opportunity of Nuplazid in Alzheimer's Disease
                • AVP-786 Profile
                • Analysis of the Clinical Development Program for AVP-786
                • Expert Insight: AVP-786
                • Expectations for Launch and Sales Opportunity of AVP-786 in Alzheimer's Disease
                • AXS-05 Profile
                • Analysis of the Clinical Development Program of AXS-05
                • Expert Insight: AXS-05
                • Expectations for Launch and Sales Opportunity of AXS-05 in Alzheimer's Disease
                • Adlarity Profile
                • Analysis of Clinical Development Program for Adlarity
                • Expert Insight: Adlarity
                • Expectations for Launch and Sales Opportunity of Adlarity in Alzheimer's Disease
                • Recent Late-Phase DMT Failures in AD
              • Early-Phase Pipeline Analysis
                • Select Disease-Modifying Compounds in Phase II Development for Alzheimer's Disease
                • Select Symptomatic Compounds in Phase II Development for Alzheimer's Disease
                • Select Behavioral Compounds in Phase II Development for Alzheimer's Disease
            • Access & Reimbursement Overview
              • Region-Specific Reimbursement Practices
                • Key Market-Access Considerations in Alzheimer's Disease: United States
                • General Reimbursement Environment: United States
                • Key Market-Access Considerations in Alzheimer's Disease: EU5
                • General Reimbursement Environment: EU5
                • Key Market-Access Considerations in Alzheimer's Disease: Japan
                • General Reimbursement Environment: Japan
            • Appendix
              • Key Abbreviations Related to Alzheimer's Disease
              • Brands, Marketers, and Generic Availability of Current Therapies Used for Alzheimer's Disease by Market
              • Alzheimer's Disease Bibliography

          Author(s): Meher Baba Kumar Nakka ; Oliver Blandy, M.Sc.

          Meher Baba Kumar Nakka, M.S.(Pharm.), is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. In this capacity, he works on a range of neurological indications, such as pain and migraine, and neurodegenerative disorders, such as Alzheimer’s disease. He holds a bachelor’s degree in pharmacy from Jawaharlal Nehru Technological University in Hyderabad and a master’s degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research in Mohali.

          Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.


          Related Reports

          Alzheimer's Disease | Disease Landscape and Forecast | G7 | 2020

          The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives—i...

          View Details

          Alzheimer's Disease - Epidemiology - Mature Markets

          DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key...

          View Details